All In Biotech

NDA 216665 · Soleno

Vykat Xr

Diazoxide Choline · Oral

Breakthrough therapyPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Mar 26, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Mar 26, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

13

5 Phase 3, 0 recruiting

FAERS reports

690

134 serious, 7 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 26, 2025.

VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). ( 1 )

Mechanism: The exact mechanism of action of diazoxide choline in the treatment of hyperphagia in patients 4 years of age and older with Prader-Willi syndrome (PWS) is unknown.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 26, 2025 Original approval · Type 2 - New Active Ingredient · priority review Breakthrough therapyOrphanLabelMedication GuideLetter
3 products under this application
  • VYKAT XR · DIAZOXIDE CHOLINE 75MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • VYKAT XR · DIAZOXIDE CHOLINE 150MG · TABLET, EXTENDED RELEASE, ORAL · Prescription
  • VYKAT XR · DIAZOXIDE CHOLINE 25MG · TABLET, EXTENDED RELEASE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Diazoxide Choline" as an intervention, any sponsor and status, largest first.

All 13 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • oedema peripheral135
  • peripheral swelling98
  • weight increased97
  • drug ineffective95
  • blood glucose increased84
  • fluid retention75
  • oedema59
  • hair growth abnormal48
  • hyperglycaemia45
  • hyperphagia45
  • abnormal behaviour44
  • hypertrichosis37

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2025172
2026518

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Soleno

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.